Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- Ghanaian court jails two Nigerians 40 years for human trafficking, cybercrime
- Houthi strikes in Yemen as Saudi Arabia braces for attacks: What we know | US-Israel war on Iran News
- Remembering the pre-Google web, when search was an experiment
- Sturgeon’s criticisms of Swinney reveal tensions in SNP ranks
- Nigeria-Cameroon, Morocco-South Africa headline blockbuster quarter-finals
- Lions’ Jahmyr Gibbs becomes highest-paid running back in history after agreeing on three-year extension
- Werner Herzog to Receive San Sebastian Film Festival’s Donostia Award
- Tinubu’s reforms yielding results, GDP rises to $375bn — Yilwatda
